Bio-Rad Laboratories Statistics
Total Valuation
BIO.B has a market cap or net worth of $9.12 billion. The enterprise value is $8.88 billion.
Important Dates
The last earnings date was Wednesday, October 30, 2024, after market close.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO.B has 5.08 million shares outstanding. The number of shares has decreased by -3.47% in one year.
| Current Share Class | 5.08M |
| Shares Outstanding | 5.08M |
| Shares Change (YoY) | -3.47% |
| Shares Change (QoQ) | -1.44% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 19.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.36 |
| PS Ratio | n/a |
| Forward PS | 3.32 |
| PB Ratio | n/a |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | 36.91 |
| P/OCF Ratio | 22.13 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 18.38, with an EV/FCF ratio of 35.96.
| EV / Earnings | n/a |
| EV / Sales | 3.44 |
| EV / EBITDA | 18.38 |
| EV / EBIT | 26.61 |
| EV / FCF | 35.96 |
Financial Position
The company has a current ratio of 6.14, with a Debt / Equity ratio of 0.19.
| Current Ratio | 6.14 |
| Quick Ratio | 4.21 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 2.52 |
| Debt / FCF | 5.62 |
| Interest Coverage | 6.80 |
Financial Efficiency
Return on equity (ROE) is -9.79% and return on invested capital (ROIC) is 2.23%.
| Return on Equity (ROE) | -9.79% |
| Return on Assets (ROA) | 1.85% |
| Return on Capital (ROIC) | 2.23% |
| Revenue Per Employee | $321,321 |
| Profits Per Employee | -$96,973 |
| Employee Count | 8,030 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | -226.50M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.58% in the last 52 weeks. The beta is 0.94, so BIO.B's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +11.58% |
| 50-Day Moving Average | 332.42 |
| 200-Day Moving Average | 314.20 |
| Relative Strength Index (RSI) | 99.59 |
| Average Volume (20 Days) | 27 |
Short Selling Information
The latest short interest is 1, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 1 |
| Short Previous Month | 3 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.20 |
Income Statement
In the last 12 months, BIO.B had revenue of $2.58 billion and -$778.69 million in losses. Loss per share was -$27.41.
| Revenue | 2.58B |
| Gross Profit | 1.41B |
| Operating Income | 333.89M |
| Pretax Income | n/a |
| Net Income | -778.69M |
| EBITDA | 483.49M |
| EBIT | 333.89M |
| Loss Per Share | -$27.41 |
Full Income StatementBalance Sheet
The company has $1.62 billion in cash and $1.39 billion in debt, giving a net cash position of $234.38 million or $46.17 per share.
| Cash & Cash Equivalents | 1.62B |
| Total Debt | 1.39B |
| Net Cash | 234.38M |
| Net Cash Per Share | $46.17 |
| Equity (Book Value) | 7.49B |
| Book Value Per Share | 267.46 |
| Working Capital | 2.56B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $412.00 million and capital expenditures -$164.93 million, giving a free cash flow of $247.07 million.
| Operating Cash Flow | 412.00M |
| Capital Expenditures | -164.93M |
| Free Cash Flow | 247.07M |
| FCF Per Share | $48.67 |
Full Cash Flow StatementMargins
Gross margin is 54.54%, with operating and profit margins of 12.94% and -30.18%.
| Gross Margin | 54.54% |
| Operating Margin | 12.94% |
| Pretax Margin | -38.96% |
| Profit Margin | -30.18% |
| EBITDA Margin | 18.74% |
| EBIT Margin | 12.94% |
| FCF Margin | n/a |
Dividends & Yields
BIO.B does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.47% |
| Shareholder Yield | 3.47% |
| Earnings Yield | -8.54% |
| FCF Yield | 2.71% |
Analyst Forecast
The average price target for BIO.B is $411.00, which is 22.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $411.00 |
| Price Target Difference | 22.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 3.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO.B has an Altman Z-Score of 3.43 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.43 |
| Piotroski F-Score | 6 |